Pathology’s David Wald explains how immunotherapy platforms are transforming cancer treatment
Dr. David Wald on Immunotherapy Platforms and U.S.-Saudi Clinical Trial Collaboration
Los Angeles Times: David Wald, professor in the Department of Pathology and Co-Leader of the Immune Oncology Program at Case Comprehensive Cancer Center, discussesd what people should know about immunotherapy platforms and how they’re transforming cancer treatment.
